European LeukemiaNet clinical signs and symptoms as prognostic markers in polycythemia vera during ruxolitinib
Year: 2026
Type: article
Study design: Observational Study
Abstract: European LeukemiaNet defines the clinical signs and symptoms (CSSs) of polycythemia vera (PV) as progressive splenomegaly, leukocytosis, thrombocytosis, inadequate hematocrit control, and cardiovascular risk factors. In PV patients receiving hydroxyurea, CSSs indicate a phenotype with higher thrombosis risk across the standard risk categories. However, the prognostic value of CSSs for thrombosis or progression to secondary myelofibrosis (SMF) or acute leukemia (AL) during second-line ruxolitinib therapy remains unknown. We assessed the incidence rate ratios (IRRs) of thrombosis and disease progression during ruxolitinib treatment, and the prognostic impact of CSSs at treatment initiation, in 254 PV patients from the PV-ARC multicenter cohort. CSSs were identified in 50.4% of patients, with similar proportions in low- and high-risk groups (50% vs 50.5%). The IRRs for thrombosis and progression to SMF/AL were 1.0 and 4.2 %p‑y, respectively. Conventional thrombotic risk categories did not predict thrombosis or progression. In contrast, CSSs were associated with higher IRRs of both thrombosis (1.8 vs 0 %p‑y, p = 0.05) and progression (6.0 vs 2.3 %p‑y, p = 0.02). Persistent or progressive leukocytosis was the strongest predictor of disease progression. In conclusion, CSSs refine conventional risk stratification by improving prediction of thrombosis and disease progression during ruxolitinib, supporting their integration into routine clinical assessment.
Source: Leukemia
Authors: Francesca Palandri, Elena Rossi, Massimo Breccia, Elena M. Elli, Chiara Sartor, Alessandra Dedola, Alessandra Iurlo, Erika Morsia, Novella Pugliese, Roberto Latagliata, Francesco Mendicino, Alessia Tieghi, Giulia Benevolo, Gianni Binotto, Mirko Farina, Alessandra D’Addio, Mario Tiribelli, Daniela Cilloni, Monica Crugnola, Flavia Salvatore, Filippo Branzanti, Daniele Cattaneo, Fabrizio Cavalca, Emilia Scalzulli, Fabrizio Pane, Francesco Lanza, Florian H. Heidel, Giuseppe A. Palumbo, Valerio De Stefano
Institutions: Istituto di Ematologia di Bologna, Università Cattolica del Sacro Cuore, Agostino Gemelli University Polyclinic, Sapienza University of Rome, University of Bologna, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Marche Polytechnic University, University of Naples Federico II, Ospedale di Belcolle, Ospedale Annunziata di Cosenza, Azienda Sanitaria Unità Locale di Reggio Emilia, Azienda Ospedaliera Citta' della Salute e della Scienza di Torino, University of Padua, Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia, University of Brescia, Azienda Unità Sanitaria Locale Della Romagna, University of Udine, University of Turin, IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola, Medizinische Hochschule Hannover, University of Catania
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $5,190
Funder: Ministero della Salute
Awards: G2654126068, G9001395237
OpenAlex ID: W7167089352
